Lipoprotein(a) Internalization in HepG2 Cells is Regulated by Proprotein Convertase Subtilisin Kexin Type 9 Through the Low-Density Lipoprotein Receptor

被引：0
|
作者：
Romagnuolo, Rocco
Seidah, Nabil G.
Koschinsky, Marlys L.
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A437
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era Getting Back on Target
    Sabatine, Marc S.
    Giugliano, Robert P.
    JAMA CARDIOLOGY, 2017, 2 (09) : 935 - 936
  • [22] Proprotein convertase subtilisin/kexin type 9 inhibitor utilization and low-density lipoprotein-cholesterol control in familial hypercholesterolemia
    Jackson, Candace L.
    Deng, Yihong
    Yao, Xiaoxi
    Van Houten, Holly
    Shah, Nilay D.
    Kopecky, Stephen
    JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (02) : 339 - 346
  • [23] Homozygous familial hypercholesterolemia in a young woman with dual gene mutations of low-density lipoprotein receptor and proprotein convertase subtilisin/kexin type 9
    Suppressa, Patrizia
    Carbonara, Concetta
    Scialpi, Natasha
    Ciavarella, Alessandro
    Sabba, Carlo
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (02) : 192 - 196
  • [24] Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation
    Tan, Lunbo
    Wang, Na
    Galema-Boers, Annet M. H.
    Vark-van der Zee, Leonie van
    van Lennep, Jeanine Roeters
    Mulder, Monique T.
    Lu, Xifeng
    Danser, A. H. Jan
    Verdonk, Koen
    MEDCOMM, 2024, 5 (09):
  • [25] A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran
    Li, Yihan
    Xue, Kefan
    Hu, Rui
    Hu, Xiao
    Guo, Ran
    Guo, Hongxia
    Li, Gang
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2025, 25 (02) : 191 - 201
  • [26] Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor
    Lambert, Gilles
    Jarnoux, Anne-Laure
    Pineau, Thierry
    Pape, Olivier
    Chetiveaux, Maud
    Laboisse, Christian
    Krempf, Michel
    Costet, Philippe
    ENDOCRINOLOGY, 2006, 147 (10) : 4985 - 4995
  • [27] Bokbunja extracts enhance low-density lipoprotein (LDL) receptor expression via attenuation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and stimulates LDL uptake in HepG2
    Song, K.
    Kim, Y.
    Kim, Y.
    Lee, H.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [28] Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin tyoe-9 and is required for the degration of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
    Jang, Hyun-Duk
    Lee, Sang Eun
    Yang, Jimin
    Lee, Hyun-Chae
    Shin, Dasom
    Lee, Hwan
    Lee, Jaewon
    Jin, Sooryeonhwa
    Kim, Soungchan
    Lee, Seung Ji
    You, Jihye
    Park, Hyun-Woo
    Nam, Ky-Youb
    Lee, Sang-Hak
    Park, Sahng Wook
    Kim, Jin-Soo
    Kim, Sang-Yeob
    Kwon, Yoo-Wook
    Kwak, Soo Heon
    Yang, Han-Mo
    Kim, Hyo-Soo
    EUROPEAN HEART JOURNAL, 2020, 41 (02) : 239 - +
  • [29] Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value
    Mark, Daniel B.
    Richman, Ilana
    Hlatky, Mark A.
    JAMA CARDIOLOGY, 2017, 2 (10) : 1066 - 1068
  • [30] Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events
    O'Keefe, James H.
    DiNicolantonio, James J.
    Lavie, Carl J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 119 (04): : 565 - 571
12345